KR102171133B1 - Skin external composition comprising centella asiatica extract and papaver rhoeas extract - Google Patents

Abstract

The present invention relates to a composition for external application for skin comprising a natural material, and more particularly, by containing a mixed extract including centella asiatica extract and corn poppy extract as an active ingredient, it has a skin soothing effect, a skin moisturizing effect, an anti-inflammatory effect and an anti-allergic effect. It provides cosmetic and pharmaceutical compositions that are excellent and can be usefully used for the prevention, improvement and treatment of skin diseases.

Description

A composition for external application for skin comprising centella asiatica extract and corn poppy extract {SKIN EXTERNAL COMPOSITION COMPRISING CENTELLA ASIATICA EXTRACT AND PAPAVER RHOEAS EXTRACT}

The present invention relates to a composition for external application for skin comprising a natural material, and more particularly, it contains a mixed extract including centella asiatica extract and corn poppy extract as an active ingredient to be usefully used for skin soothing, skin moisturizing, anti-inflammatory or anti-allergic It relates to a cosmetic and pharmaceutical composition that can be.

Skin is divided into three layers of epidermis, dermis, and subcutaneous fat tissue in order from the outside, and is a tissue that covers the outside of the body and protects the body from environmental factors such as various external stimuli, obstacles, and dryness. It functions to protect and regulate internal organs and other internal organs.

Skin irritation may include environmental factors such as sunlight, wind, cold and dry air, infections, shaving scratches, repetitive or excessive washing or living factors such as bathing, mechanical scratches or damage, and physical and chemical factors and sensitivity or It may be different depending on genetic factors.

In order to maintain healthier and more beautiful skin by preventing skin irritation caused by such internal and external factors, skin aging, etc., physiologically active substances obtained from various animals, plants, microorganisms, etc. are added to external skin preparations such as cosmetics. Efforts have been made to maintain skin health by maintaining skin's own function and activating skin cells by using it to promote skin metabolism, and various studies have been conducted accordingly.

Centella asiatica is a perennial creeping medicinal plant that lives mainly in South Asia, and in Korea, it grows in low wetlands in Jeju Island and the central and southern regions. The major ingredients of centella asiatic are madecassoside, madecassic acid, asiaticoside, and asiatic acid. These ingredients have been used in the treatment of skin wounds and chronic ulcers, and have been reported to have good antibacterial properties and are effective in skin diseases and antirheumatoid arthritis. In addition, effects such as promoting the cell cycle of skin cells, promoting proliferation and collagen synthesis, and inhibiting skin aging have been reported (Jieun Park, 2010), and studies to utilize them are active.

As a related prior art, Korean Patent Laid-Open No. 10-2017-0103172 discloses centella extract, ceramide and birch sap by utilizing the moisturizing effect based on maintaining moist skin by strengthening the skin barrier of ceramide and controlling the moisturizing factor. A cosmetic composition having the effect of relieving skin irritation and improving skin barrier, including, is disclosed, and Korean Patent Laid-Open Patent No. 10-2015-0045049 discloses a liquid extract of cypress leaves, liquid extract of pine needles, liquid extract of pine needles, and green tea leaves along with centellar liquid extract. A cosmetic composition for moisturizing the skin containing a fermented extract obtained after fermenting the liquid extract and alkaline ionized water as active ingredients and a method for manufacturing the same are disclosed, and Korean Patent Publication No. 10-2007-0111785 discloses centella and magnolia extracts 1: A skin protective composition for synergistic antibacterial and skin moisturizing, comprising in a ratio of 0.3 to 3, is disclosed.

As described above, by using centella asiatica extract on the skin, it has already been known that it has a wound healing effect. However, it was not known that studies on corn poppy extract or the use of centella asiatica extract together with corn poppy extract could synergistically increase the effect of the Byungchul extract.

Korean Patent Publication No. 10-2017-0103172 Korean Patent Publication No. 10-2015-0045049 Korean Patent Publication No. 10-2007-0111785

The present invention is to solve the above problems, by containing a mixed extract including centella asiatica extract and corn poppy extract as an active ingredient, cosmetic and pharmaceutical products that can be usefully used for skin soothing, skin moisturizing, anti-inflammatory or anti-allergic It is an object to provide a composition.

According to an aspect of the present invention, it provides a cosmetic composition comprising a mixed extract comprising centella asiatica extract and corn poppy extract.

The mixed extract may provide a cosmetic composition comprising centella extract and corn poppy extract in a weight ratio of 1: 0.2 to 1: 10.

The mixed extract may provide a cosmetic composition, characterized in that it contains 0.001 to 50% by weight based on the total weight of the cosmetic composition.

The cosmetic composition may provide a cosmetic composition, characterized in that for skin soothing, skin moisturizing, anti-inflammatory or anti-allergic use.

According to another aspect of the present invention, there is provided a pharmaceutical composition for skin soothing comprising a mixed extract comprising centella asiatica extract and corn poppy extract as an active ingredient.

According to another aspect of the present invention, there is provided a quasi-drug composition for skin soothing comprising a mixed extract including centella asiatica extract and corn poppy extract as an active ingredient.

According to the cosmetic and pharmaceutical composition containing the mixed extract including centella asiatica extract and corn poppy extract according to the present invention as an active ingredient, skin soothing effect, skin moisturizing effect, anti-inflammatory effect and anti-allergic effect are excellent, so that the prevention of skin diseases, It can be usefully used for improvement and treatment.

Hereinafter, an embodiment of the present invention will be described in detail. However, this is presented as an example, and the present invention is not limited thereby, and the present invention is only defined by the scope of the claims to be described later.

In describing the present invention, when it is determined that a detailed description of a related known configuration or function may obscure the subject matter of the present invention, a detailed description thereof will be omitted.

In describing the constituent elements of the present invention, terms such as first, second, A, B, (a), and (b) may be used. These terms are only used to distinguish the component from other components, and the nature, order, or order of the component is not limited by the term.

In describing the present invention, the terms'about','substantially','degree', etc. of degree are used in or close to the numerical value when manufacturing and material tolerances specific to the stated meaning are presented. , In order to aid the understanding of the present invention, accurate or absolute numerical values are used to prevent unscrupulous infringers from unfairly using the stated disclosure.

In the present invention, the extract is a liquid component obtained by immersing the target substance in various solvents and then extracting for a certain period of time at room temperature, low temperature or warm state, and the resultant product such as a solid component obtained by removing the solvent from the liquid component. it means. In addition, in addition to the result, it can be comprehensively interpreted as including all of the resulting diluted solution, the concentrated solution thereof, the fraction thereof, the crude product, and the purified product.

In the present invention, the term'prevention','improvement' or'treatment' refers to suppression, alleviation or elimination of the appearance or development of one or more symptoms related to a disease or disease.

In the present invention, the term'external preparation for skin' is a concept encompassing the entire composition applied to the skin, for example, various cosmetics such as basic cosmetics, makeup cosmetics, and hair cosmetics, skin care products, ointments, creams, lotions It is a concept including pharmaceutical compositions for topical administration including pharmaceuticals such as pharmaceuticals and quasi-drugs.

The external preparation for skin according to an embodiment of the present invention may contain a mixed extract including centella asiatica extract and corn poppy extract.

In the present invention, Centella asiatica is a perennial grass belonging to the Ranunculus family that blooms white or light purple flowers on small fan-shaped leaves with serrated edges around them. Because it grows in warm and humid areas, it is commonly found in the mountains and fields of southern islands such as Jeju Island in Korea. In India, injured tigers have been used as medicines since long ago, after seeing them roll over and heal them in places with a lot of centella.

As the main active ingredients of centella asiatic acid, madecassoside, madecassic acid, asiaticoside, and asiatic acid are known. Asiatic acid is known to have anti-cancer effects in various carcinomas, and asiaticoside or its derivatives are known to be effective in skin ulcers, extensive trauma treatment, skin veins, senile ulcers, erosive skin ulcers, and alopecia hanseong. . Madecassic acid in the leaves and stems of Centella asiatica is known to heal inflammation and to heal wounds such as tumors and ulcers, and Centella asiatica extract promotes collagen synthesis to enhance skin elasticity and to heal wounds. It is excellent in skin treatment, improves acne and atopy, and is known to have skin regeneration effect and pore reduction effect with collagen.

In the present invention, Papaver rhoeas ) is called Umiincho (虞美人草) and Baby opium flower, and is a biennial plant in the poppy family. Flowers are usually red, but depending on the variety, they are multicolored and bloom from May to June, and each flower hangs at the end of the branch. Before flowers bloom, the buds face down, but when they bloom, they face up. There are 2 sepals, green, the edges are white, and hairs are formed on the outside. The petals are 4, alternately, somewhat round, and the stamens are many, the ovaries are obovate, hairless, the flower is radial, and the fruits are capsules, which are wide obovate. It is known that the flowers of the corn poppy, the ground part, and the outpost have soothing, hypnotic, and analgesic effects.

Plants of the poppy family to which the poppy belongs have various phytochemicals such as alkaloids, anthocyanins, and phenolic compounds, for example, rhoeadine, rhoeadic acid, papaveric acid, and lea It has major phytochemical components such as rhoeagenine, anthocyanin (cyanidine, mecocyanin), berberine, and protoberberine. Although the major phytochemical components are known to have antioxidant, antibacterial, anti-inflammatory, anti-fibrotic, and skin-protective effects, the possibility of application is expected to be high.However, medical or cosmetic studies on corn poppy have not been actively conducted. In addition, its utility is not high.

In the present invention, it was confirmed that the extract of corn poppy further increases the synergistic effect of the mixture with other plant extracts.

That is, it has already been known that the centella asiatica extract has the effect of healing wounds on the skin, but the present inventors have used the centella asiatica extract and corn poppy extract together to calm the skin, moisturize the skin, anti-inflammatory or anti-inflammatory than the case of using them respectively. It has been found that the allergic effect is synergistically excellent, and that synergistic effect can be further increased by controlling the blending ratio.

In the present invention, the centella asiatica extract and corn poppy extract may be extracted from various organs of natural, hybrid, and mutant plants.

In the present invention, the centella asiatica extract can be extracted from plant tissue cultures as well as from outposts, roots, above-ground parts, stems, leaves, flowers, trunks of fruits, and skins of fruits.

In the present invention, the corn poppy extract can be extracted from plant tissue cultures as well as the outposts, roots, above-ground parts, stems, leaves, flowers, trunks of fruits, and skins of fruits.

The method of extraction or the kind of solvent for obtaining the extract is not particularly limited. As the solvent, in addition to water, alcohols such as ethanol, methanol, propanol, glycerin, and propylene glycol, organic solvents such as ether, acetone, ethyl acetate, chloroform, and hexane, or a combination thereof can be used. However, from the viewpoint of safety, it is preferable to extract using water, ethanol, or a mixed solution thereof.

The method for obtaining the extract is not particularly limited, but specifically, the centella, corn poppy, roots, stems, leaves, fruits, flowers, dried products and processed products thereof are immersed in the solvent and extracted at room temperature. Methods such as cold sediment extraction, heating extraction, ultrasonic extraction by applying ultrasonic waves, and reflux extraction using a reflux cooler may be used.

In the present invention, the mixed extract may be an extract obtained by mixing extracts of centella asiatica and corn poppy at an appropriate weight mixing ratio, and may be extracted after mixing centella asiatica and corn poppy at an appropriate weight mixing ratio. The mixed extract was confirmed to be effective in soothing the skin, moisturizing the skin, anti-inflammatory or anti-allergic than the single extract of centella and corn poppy, and it can be seen that it has excellent synergistic action.

The mixed extract may include centella asiatica extract and corn poppy extract in a weight ratio of 1: 0.2 to 1: 10, preferably 1: 0.5 to 1: 5, preferably 1: 1 to 1: 3. If the weight ratio of the centella extract to the corn poppy extract is less than 0.2, the effect is not sufficiently exhibited, and if it exceeds 10, the effect is rather reduced.

The extract may be used in the form of a solution, but may be further filtered to distill the extraction solvent, and then dried under reduced pressure or freeze-dried to form a powder, or a concentrated one may be used. Moreover, those obtained by fractionating and purifying these extracts by organic solvent fractionation, column chromatography, or the like can also be used. Further, purification treatment such as deodorization and decolorization may be applied.

In the present invention, the active ingredient of the mixed composition is 0.001 to 50% by weight, preferably 0.01 to 50% by weight, preferably 0.01 to 20% by weight, preferably 0.05 to 20% by weight based on the total skin external preparation composition. % By weight, preferably 0.1 to 20% by weight, preferably 0.5 to 20% by weight, preferably 0.5 to 10% by weight. When the weight of the mixed composition is less than 0.001% by weight, there may be a slight problem in efficacy and effect, and when it exceeds 50% by weight, there may be problems in skin stability or formulation.

According to an embodiment of the present invention, the external preparation for skin containing a mixed extract including centella asiatica extract and corn poppy extract may be a cosmetic composition.

In the present invention, the cosmetic composition has skin soothing, skin moisturizing, anti-inflammatory or anti-allergic effects by containing the mixed composition as an active ingredient.

In the present invention, the skin soothing means that the skin cells are damaged by internal or external stimuli, such as reddened or sensitive skin due to sunlight or ultraviolet rays, naturally sensitive skin or irritated skin, etc. It refers to recovery, but is not particularly limited thereto.

In the present invention, the skin moisturizing means suppressing moisture loss so that moisture from the skin does not disappear quickly and stays on the skin for a long time, the effect of supplying moisture to the skin, and strengthening the skin barrier.

In the present invention, the anti-inflammatory is a defense mechanism, which means resistance to inflammation, and the inflammation is caused by the signaling system of the immune response system, and specifically, atopic dermatitis, allergic dermatitis, inflammatory skin disease, immunity There are diseases and asthma, but are not necessarily limited thereto.

In the present invention, the anti-allergic is meant to include improvement, treatment, and prevention (inhibition or delay of onset) of allergic diseases, and as the allergic disease, the activation of mast cells, such as degranulation of mast cells, is mediated. It refers to a pathological symptom caused by a reaction, and these allergic diseases include atopic dermatitis, allergic asthma, allergic rhinitis, allergic conjunctivitis, and allergic dermatitis. allergic dermatitis), allergic contact dermatitis, allergic keratitis, and the like, but are not particularly limited thereto.

The cosmetic composition includes softening lotion, nutritional lotion, moisture cream, nutrition cream, massage cream, nutrition lotion, essence, ampoule, gel, eye cream, oil, foundation, cleansing cream, cleansing foam, cleansing water, shampoo, conditioner, pack, It may be formulated as one or more selected from the group consisting of spray and powder.

Specifically, the cosmetic composition may be prepared in a general emulsion formulation and solubilization formulation. For example, lotions such as soft toner or nutritious lotion, facial lotion, body lotion, etc., nutritional cream, moisturizing cream, cream such as eye cream, essence, cosmetic ointment, spray, gel, pack, sunscreen, makeup base, liquid It may be formulated with a makeup remover such as a foundation type, a solid type, or a spray type, a powder, a cleansing cream, a cleansing lotion, a cleansing oil, or a detergent such as a cleansing foam, soap, or body wash, but is not limited thereto.

In the cosmetic composition, in addition to the essential ingredients in each formulation, other ingredients may be appropriately blended within a range that does not impair the object according to the present invention depending on the type of formulation or purpose of use.

The cosmetic composition may contain a generally acceptable carrier, for example, oil, water, surfactant, moisturizer, lower alcohol, thickener, chelating agent, colorant, preservative, fragrance, etc. may be appropriately blended, but are limited thereto. no.

The acceptable carrier may vary depending on the formulation of the cosmetic composition.

For example, when formulated as an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or A mixture thereof may be used, but is not limited thereto.

When the cosmetic composition is formulated as a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or a mixture thereof may be used as a carrier component, and in the case of spray, chlorofluorohydro It may further include a propellant such as carbon, propane, butane or dimethyl ether, but is not limited thereto.

When the cosmetic composition is formulated as a solution or emulsion, a solvent, a solubilizing agent, or an emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol , Butylene glycol oil may be used, and in particular, cottonseed oil, peanut oil, corn seed oil, olive oil, castor oil and sesame oil, glycerol fatty ester, polyethylene glycol or fatty acid ester of sorbitan may be used, but limited thereto. It does not become.

When the cosmetic composition is formulated as a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester , Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used, but the present invention is not limited thereto.

When the cosmetic composition is formulated with soap, as a carrier component, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionate, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars, etc. It may be used, but is not limited thereto.

When the cosmetic composition is formulated as a pack, a peel-off pack containing polyvinyl alcohol, etc., a wash off containing a pigment such as kaolin, talc, zinc oxide, or titanium dioxide in a general emulsion type cosmetic All forms of a pack or a mask sheet pack are included, but are not limited thereto.

The cosmetic composition is a fatty substance, an organic solvent, a solubilizer, a thickener, a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, and a fragrance, which are commonly used in the industry depending on the quality or function of the final product. , Surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic activators, commonly used in cosmetics It may additionally contain adjuvants commonly used in the field of cosmetology or dermatology, such as any other ingredients.

According to an embodiment of the present invention, the external preparation for skin containing a mixed extract including centella asiatica extract and corn poppy extract may be a pharmaceutical composition available for skin soothing, skin moisturizing, anti-inflammatory or anti-allergic use.

The pharmaceutical composition may further include a pharmaceutically acceptable carrier.

In the present invention, the term'pharmaceutically acceptable carrier' refers to a carrier or diluent that does not irritate an organism and does not inhibit the prophylactic or therapeutic activity and properties of the pharmaceutical composition according to the present invention. As acceptable pharmaceutical carriers for compositions formulated as liquid solutions, sterilization and biocompatible ones, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol And one or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as needed.

In addition, the pharmaceutically acceptable carrier may include a non-naturally occurring carrier.

The pharmaceutical composition may be administered single or multiple in a pharmaceutically effective amount.

In the present invention, the term'pharmaceutically effective amount' means an amount sufficient to prevent or treat a disease at a reasonable benefit/risk ratio applicable to medical prevention or treatment, and the effective dose level is the severity of the disease, drug Activity of the patient, the patient's weight, health, sex, the patient's sensitivity to the drug, the administration time of the composition of the present application used, the route of administration and the rate of excretion, the treatment period, and the drug used in combination or concurrently with the composition of the present application used It can be determined by the factors involved and other factors well known in the medical field.

According to an embodiment of the present invention, the external preparation for skin containing a mixed extract including centella asiatica extract and corn poppy extract may be a quasi-drug composition available for skin soothing, skin moisturizing, anti-inflammatory or anti-allergic use.

In the present invention, the term'quasi-drug' refers to items that have a milder action than pharmaceuticals among items used for the purpose of diagnosing, treating, improving, reducing, treating or preventing diseases of humans or animals, for example, the Korean Pharmacist Act. According to the report, quasi-drugs exclude items used for pharmaceutical purposes, and include products used for the treatment or prevention of diseases of humans and animals, and products with minor or no direct action on the human body.

The quasi-drug composition may be prepared in a form selected from the group consisting of a body cleanser, foam, soap, mask, ointment, cream, lotion, essence, and spray, but is not limited thereto.

When the mixed extract including centella asiatica extract and corn poppy extract according to the present invention is used as a quasi-drug additive, the mixed extract may be added as it is or may be used together with other quasi-drug or quasi-drug ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use.

Hereinafter, the present invention will be further described through manufacturing examples and test examples. These examples are for explaining the present invention more specifically, and the scope of the present invention is not limited to these examples.

[ Example ]

[ Manufacturing example ]

[Preparation Example 1] Preparation of extract

1. Preparation of Centella asiatica extract

After washing the upper part of Centella asiatica with distilled water and drying at 50°C, it was pulverized with a grinder to powder. 1 L of 70% (w/v) ethanol was added to 100 g of Centella asiatica powder, followed by immersion for 3 hours at room temperature for extraction. After filtering the obtained extract, the filtrate was concentrated under vacuum to obtain 4.5 g of Centella asiatica extract.

2-1. Preparation of above-ground corn poppy extract

The above-ground part of flowering corn poppy was washed clean with distilled water, dried at 50°C, and pulverized with a grinder to form powder. 1 L of 70% (w/v) ethanol was added to 100 g of the above-ground corn poppy powder, and extracted by immersing for about 3 hours at room temperature. After filtering the obtained extract, the filtrate was concentrated under reduced pressure under vacuum to obtain 3.9 g of the above-ground corn poppy extract. .

2-2. Preparation of poppy flower extract

The poppy flowers were washed with distilled water, dried at 50° C., pulverized with a grinder, and powdered. 1 L of 80% (w/v) ethanol was added to 100 g of poppy flower powder, and extracted by immersing for about 3 hours at room temperature. After filtering the obtained extract, the filtrate was concentrated under vacuum to obtain 3.5 g of corn poppy flower extract. .

3. Preparation of aloe extract

Aloe was washed clean with distilled water, dried, pulverized with a blender, and powdered. A solvent mixed with purified water and ethanol at a ratio of 5:5 was added to the aloe powder in an amount of about 10 times by volume, followed by extraction twice. After performing the above extraction, after filtering with a 400 mesh filter cloth, the obtained filtrate was concentrated using a vacuum concentrator to obtain an extract powder.

[Production Example 2] Preparation of the composition

Compositions according to Examples and Comparative Examples were prepared in the composition shown in Table 1 below by using the Byeongpung extract prepared by Preparation Example 1, the above-mentioned corn poppy extract, the poppy flower extract, and the aloe extract.

Centella asiatica extract Corn poppy
extract Poppy Flower Extract Aloe extract Untreated group - - - - Comparative Example 1 One - - - Comparative Example 2 - One - - Comparative Example 3 One - - One Example 1 One 0.2 - - Example 2 One - 0.5 - Example 3 One One - - Example 4 One - 2 - Example 5 One 3 - - Example 6 One 5 - - Example 7 One 10 - - Weight ratio

[Production Example 3] Preparation of cosmetics

As shown in Table 2 below, toners, ampoules, lotions, etc. containing the composition of the present invention as an active ingredient were prepared according to a conventional cosmetic manufacturing method.

ingredient Example 8
(toner) Example 9
(ample) Example 10
(Lotion) Example 1 1.00 Example 3 1.50 Example 4 2.00 Carbomer 0.20 0.40 0.60 Dipropylene glycol 8.00 10.00 4.00 Butylene Glycol 2.00 2.00 4.00 glycerin 2.00 5.00 4.00 Trehalose 0.50 1.00 0.10 Betaine 0.50 0.50 0.10 Sodium hyaluronate 0.01 0.02 - Xanthan gum - - 0.05 Ethylhexyl palmitate - - 4.00 Cyclopentasiloxane - - 3.00 Ceteares-30 - - 3.00 Cetyl alcohol - - 3.00 Hydrogenated poly (C-14 olefin) - - 3.00 Sodium Stearoyl Glutamate - - 0.50 1,2-hexanediol 1.00 1.00 1.00 ethanol 1.00 - - PEG-40 Hydrogenated Castor Oil 0.25 0.40 - Hydrolyzed Jojoba Ester 0.10 - - Spices 0.02 0.05 0.04 Arginine 0.20 0.40 0.60 Ethylhexyl glycerin 0.15 0.15 0.15 Caprylyl Glycol 0.15 0.15 0.15 Purified water Up to 100 Up to 100 Up to 100 Unit: wt%

[ Test example ]

[Test Example 1] Skin keratinocyte culture

HaCaT cells, which are skin keratinocytes, are Dr. Pre-sale from CG Hyun (Jeju National University, Korea), using Dulbecco's Modified Eagle's Medium (DMEM) medium containing 100 units/ml penicillin-streptomycin and 10% fetal bovine serum (FBS) at 37℃, 5% CO ₂ And subcultured at intervals of 3 to 4 days.

[Test Example 2] Cytotoxicity evaluation (EZ-cytox assay)

The EZ-cytox assay is a representative method of measuring cell viability using the principle that water solution tetrazolium salt (WST) reacts with dehydrogenase in living cells to produce orange water-soluble formazan.

To check the toxicity in skin keratinocytes, HaCaT cells were dispensed into a 96 well plate at 5 X 10 ⁴ cells/mL using DMEM medium added with 10% FBS, and under 37℃, 5% CO ₂ conditions for 18 hours. During incubation. The composition to be evaluated was treated by replacing the cultured HaCaT cells with serum-free DMEM. Thereafter, EZ-cytox was added to each well and reacted for 30 minutes at 37°C and 5% CO ₂ conditions, and then absorbance was measured at 450 nm using a microplate reader. The average absorbance value for each sample group was obtained, and the cell viability was evaluated by comparing it with the absorbance value of the control group.

division Treatment concentration (μg/mL) Cytotoxicity HaCaT cell viability (%) Untreated group - 100 Comparative Example 1 100 103 ± 2.1 Comparative Example 2 100 101 ± 1.2 Comparative Example 3 100 103 ± 1.3 Example 1 100 101 ± 4.1 Example 2 100 105 ± 3.2 Example 3 100 104 ± 1.1 Example 4 100 105 ± 3.2 Example 5 100 101 ± 4.1 Example 6 100 104 ± 1.1 Example 7 100 101 ± 4.1

Looking at Table 3, cytotoxicity was not observed in both Comparative Examples 1 to 3 and Examples 1 to 7 which are compositions according to the present invention.

[Test Example 3] Skin soothing (relieving skin irritation) effect

Human fibroblast cell line (ATCC, Cat. No. CRL-2076) was mixed at a density of 1 X 10 ⁵ cells/mL, and a collagen solution containing 200 µl of fibroblasts each was added to a 10 mm diameter insert to prepare the dermis. . After preparation of the dermis, DMEM containing 10% FBS was replaced every 2 days and cultured for 7 days. 10 µl of sodium lauryl sulfate (SLS), which is a skin irritant, was administered on the cultured dermis, and after 4 hours, 10 µl of the composition prepared according to Table 1 was applied, followed by incubation at 37° C. and 5% CO ₂ for 24 hours. DMSO was used as the solvent for the SLS and the extract, and the concentration was taken as the weight percent of the toxic substance to the solution. IL-1α was measured at 450 nm with an ELISA-reader (enzyme-linked immunosorbent assay) using the Human IL-1α assay kit (Endogen Inc. Boston, MA, USA) by taking a medium sample.

division Treatment concentration (μg/mL) IL-1α release (pg/mL) Untreated group (SLS) - 92.1 Comparative Example 1 100 90.5 Comparative Example 2 100 85.3 Comparative Example 3 100 79.1 Example 1 100 60.8 Example 2 100 56.1 Example 3 100 50.3 Example 4 100 52.2 Example 5 100 58.4 Example 6 100 67.2 Example 7 100 70.4

Looking at Table 4, it can be seen that the treatment of Examples 1 to 7, which are compositions according to the present invention, suppresses the production of IL-1α, so that the alleviating effect against skin irritation is higher than Comparative Examples 1 to 3.

[Test Example 4] Anti-allergic experiment (β-hexosaminidase release amount measurement)

β-hexosaminidase is an enzyme contained in mast cells and is released along with histamine when mast cells are activated by an immune reaction. Therefore, β-hexosaminidase can be used as an indicator of mast cell degranulation (Planta Med. 64, 577-578 (1998)).

RBL-2H3 cells were cultured by dispensing into 24 well plates at 5 X 10 ⁵ cells/mL using EMEM (Eagle's Minimum Essential Medium) medium containing 10% FBS and glutamine. The medium used at this time was one containing 0.5 μg/ml of mouse monoclonal IgE (mouse monoclonal IgE) in EMEM medium, and cultured in an incubator at 37° C. and 5% CO ₂ for 24 hours.

Rinse the cells using 500 μl of siraganian buffer I (pH 7.2, sodium chloride 119 mM, potassium chloride 5 mM, magnesium chloride 0.4 mM, PIPES 25 mM, and sodium hydroxide 40 mM) per well. 160 [mu]l of Nian buffer II (glucose 5.6 mM, potassium chloride 1 mM and 0.1% BSA added) was added, followed by incubation at 37° C. and 5% CO _{2 in an} incubator for 10 minutes. After treatment with the composition prepared according to Table 1, incubation was performed in a 37°C, 5% CO ₂ incubator for 20 minutes, and antigen (1 µg/ml, DNP-BSA) was treated for 10 minutes. The reaction was stopped by taking an ice bath for about 10 minutes and centrifugation was performed. The supernatant was treated with 20 µl of a substrate (1mM ρ-nitrophenyl-N-acetyl-β-D-glucosamined) and incubated for 1 hour in a 37°C, 5% CO ₂ incubator, and 0.1M Na ₂ CO ₃ / NaHCO ₃ was added to stop the reaction. The absorbance was measured at 405 nm using an ELISA reader, and the inhibition rate was calculated as follows, and the results are shown in Table 4.

※ Inhibition rate (%) = {1-(B-C-D)/(A-C-D)}×100

A (control): No test substance added (measurement of antigen IgE reaction)

B (Treatment group): Addition of test substance (measurement of antigen IgE reaction)

C (blank): Addition of only test substance and substrate to ELISA plate

D (No treatment group): No antigen, IgE and test substance added

division Treatment concentration (μg/mL) Inhibition rate (%) Comparative Example 1 100 21.3 Comparative Example 2 100 27.1 Comparative Example 3 100 15.3 Example 1 100 42.3 Example 2 100 45.5 Example 3 100 47.7 Example 4 100 51.3 Example 5 100 48.4 Example 6 100 46.2 Example 7 100 44.8

Looking at Table 5, it can be seen that the case of treating Examples 1 to 7, which are compositions according to the present invention, is higher than that of Comparative Examples 1 to 3.

[Test Example 5] Inflammation inhibition measurement

In order to confirm the anti-inflammatory effect, we tried to analyze the inhibitory activity of the production of proinflammatory cytokines (IL-6: Interleukin-6, TNF-α: tumor necrosis factor-alpha).

RAW 264.7 cells were placed in a 48 well plate and adhered for 18 hours. The composition prepared according to Table 1 and Lipopolysaccharide (LPS, 1 μg/mL) were treated together and cultured for a certain time. Then, the culture medium was centrifuged (12,000 rpm, 3 min) to measure the content of proinflammatory cytokine produced in the obtained supernatant. All samples were stored frozen (-20°C) until quantification. Proinflammatory cytokines were quantified using a mouse enzyme-linked immnunosorbent assay (ELISA) kit (R&D Systems Inc., Minneapolis, MN, USA) and the r ² value of the standard curve for the standard was 0.99 or higher.

sample Treatment concentration (μg/mL) Inhibition of TNF-α production (%) Inhibition of IL-6 production (%) Comparative Example 1 100 21.4 ± 3.9 10.8 ± 1.8 Comparative Example 2 100 28.3 ± 1.8 48.1 ± 2.9 Comparative Example 3 100 37.1 ± 3.3 30.2 ± 2.1 Example 1 100 45.5 ± 1.2 56.7 ± 1.6 Example 2 100 48.8 ± 0.5 63.7 ± 1.7 Example 3 100 57.8 ± 2.3 68.7 ± 1.8 Example 4 100 69.4 ± 3.1 73.3 ± 3.0 Example 5 100 75.3 ± 2.8 70.3 ± 3.1 Example 6 100 71.3 ± 0.8 65.3 ± 3.0 Example 7 100 68.4 ± 3.1 58.3 ± 0.9 Dexamethason 10 65.2 ± 2.3 63.1 ± 2.2

Looking at the above Table 6, it can be seen that the treatment of Examples 1 to 7, which are compositions according to the present invention, has a higher inhibition rate of proinflammatory cytokine production than Comparative Examples 1 to 3.

[Test Example 6] Confirmation of the effect of increasing the production amount of hyaluronic acid, a moisturizing factor

HaCaT cells were dispensed into a 24 well plate at 1.0 X 10 ⁵ cells/mL and cultured for 18 hours at 37°C and 5% CO ₂ . It was exchanged for Serum-free DMEM, and the composition prepared according to Table 1 was treated and incubated for 24 hours. Thereafter, the culture medium was removed, centrifuged at 15,000 rpm for 5 minutes, and the supernatant was removed and stored frozen (-20°C) until quantification. The enzyme immunoassay (ELISA: Enzyme-Linked Immunosorbent Assay) was performed using a hyaluronic acid ELISA kit (Elabscience Biotechnology Co., Ltd.) and was carried out by the method provided by the manufacturer.

Treatment concentration (μg/mL) Hyaluronic Acid production (%) Untreated group - 100 Comparative Example 1 100 136 ± 2.8 Comparative Example 2 100 102 ± 2.1 Comparative Example 3 100 175 ± 5.6 Example 1 100 210 ± 5.9 Example 2 100 216 ± 1.7 Example 3 100 222 ± 2.2 Example 4 100 218 ± 6.1 Example 5 100 204 ± 3.3 Example 6 100 198 ± 2.2 Example 7 100 187 ± 2.2 Retinoic acid 10 243 ± 0.6

Looking at Table 7 above, it can be seen that the production amount of hyaluronic acid, which is a skin moisturizing factor, is higher in the case where Examples 1 to 7, which are compositions according to the present invention, are treated more than Comparative Examples 1 to 3.

[Test Example 7] Confirmation of the effect of increasing the amount of moisturizing factor Aquaporin3 (AQP3) production

HaCaT cells were aliquoted into a 6 well plate at 4.0 X 10 ⁵ cells/mL, and cultured for 18 hours at 37°C and 5% CO ² . It was exchanged for Serum-free DMEM, and the composition prepared according to Table 1 was treated and incubated for 24 hours. After removing the culture medium for each group and washing with PBS, PBS containing no drugs that may affect protein quantification was treated. The protein was collected after lysing the cells by repeating incubation at low and room temperature. Quantification was performed using the AQP3-ELISA kit (Elabscience Biotechnology Co., Ltd) and was performed by the method provided by the manufacturer.

Treatment concentration (μg/mL) Aquaporin3 production (%) Untreated group - 100 Comparative Example 1 100 142 ± 5.4 Comparative Example 2 100 125 ± 4.8 Comparative Example 3 100 178 ± 4.3 Example 1 100 202 ± 4.8 Example 2 100 209 ± 2.6 Example 3 100 216 ± 4.2 Example 4 100 221 ± 6.2 Example 5 100 211 ± 4.2 Example 6 100 198 ± 2.9 Example 7 100 184 ± 4.8 Retinoic acid 10 234 ± 3.9

Looking at Table 8, it can be seen that the production amount of Aquaporin3, which is a skin moisturizing factor, is higher in the case where Examples 1 to 7, which are compositions according to the present invention, are treated more than Comparative Examples 1 to 3.

[Test Example 8] Measurement of transepidermal moisture loss in damaged skin

The evaluation of transepidermal moisture loss under damaged skin was performed on a total of 15 women each in their 20s and 30s, and was measured using a Vapometer (Delfin Technologies Ltd, Finland). Tape stripping (hereinafter referred to as TS) was performed on one of the subjects' forearm (inner forearm) to induce skin damage, and to a part (3 X 3 cm) of the TS-induced part in Examples 7 to 9 of Preparation Example 3 The test product thus prepared was applied, and the product was not applied to the rest of the area. The measurement method to check the degree of improvement of the transepidermal moisture loss of the skin is repeated 3 times (10s/1 time) using a Vapometer before and after the TS for each of the applied and non-applied areas, and 10 minutes after product application. Measurement was performed, and the average value was used as measurement data.

Product application area Product-free area Before TS Before (After TS) Immediately after use Before TS Before (After TS) Immediately after use Example 7
(toner) One 11.133 32 12.1 10.033 27.633 14.967 2 9.833 20.467 10.367 9.6 20.533 10.2 3 10 38.6 14.333 10.5 41.067 26.933 4 10.767 23.367 15.067 12.833 34.967 24.2 5 8.7 29.767 12.433 8.4 33.033 28.133 Average 10.0866 28.8402 12.8600 10.2732 31.4466 20.8866 Example 8
(ample) One 10.533 39.2 13.967 10.533 37.433 29.133 2 8.2 29.867 10.1 8.533 37.8 20.933 3 8.5 38.2 10.3 9.667 34.033 15.133 4 8.2 29.933 10.7 7.1 35.4 22.4 5 11.333 35.167 13.3 12.367 31.067 21.433 Average 9.3532 34.4734 11.6734 9.6400 35.1466 21.8064 Example 9
(Lotion) One 10.833 35.6 13.0335 10.283 32.533 22.05 2 9.0165 25.167 10.2335 9.0665 29.1665 15.5665 3 9.25 38.4 12.3165 10.0835 37.55 21.033 4 9.4835 26.65 12.8835 9.9665 35.1835 23.3 5 10.0165 32.467 12.8665 10.3835 32.05 24.783 Average 9.7199 31.6568 12.2667 9.9566 33.2966 21.3465

Looking at Table 9, it can be seen that the cosmetic composition containing centella asiatica and poppies, which are compositions according to the present invention, has excellent effects even when measuring transepidermal moisture loss under damaged skin. It was confirmed that the cosmetic composition containing centella asiatica and poppy, which are compositions according to the present invention, has excellent moisturizing and anti-inflammatory effects as well as skin soothing effects on damaged skin, and is therefore very effective in use as a cosmetic and pharmaceutical composition.

The above description is merely illustrative of the present invention, and those of ordinary skill in the art to which the present invention pertains will understand that the present invention may be implemented in a modified form within the scope not departing from the essential characteristics of the present invention. I will be able to Therefore, the disclosed embodiments and experimental examples should be considered from a descriptive point of view rather than a limiting point of view. The scope of the present invention is shown in the claims rather than the foregoing description, and all differences within the scope equivalent thereto should be construed as being included in the present invention.

Claims (6)

A cosmetic composition comprising a mixed extract comprising centella asiatica extract and corn poppy extract in a weight ratio of 1: 0.2 to 1: 10. delete The method of claim 1,
The mixed extract is a cosmetic composition, characterized in that containing 0.001 to 50% by weight based on the total weight of the cosmetic composition. The method of claim 1,
The cosmetic composition is a cosmetic composition, characterized in that for skin soothing, skin moisturizing, anti-inflammatory or anti-allergic use. Anti-inflammatory or anti-allergic pharmaceutical composition containing a mixed extract containing centella asiatica extract and corn poppy extract in a weight ratio of 1: 0.2 to 1: 10 as an active ingredient. A quasi-drug composition for skin soothing containing a mixed extract containing centella asiatica extract and corn poppy extract in a weight ratio of 1: 0.2 to 1: 10 as an active ingredient.